Pharma & Biotech M&A Tracker (2025–2026): Deal Values, Buyers & Acquisition Status
A continuously updateable reference to major pharmaceutical and biotechnology mergers and acquisitions, including acquisition prices, strategic rationale, therapeutic focus, and transaction status.
Last reviewed: November 3, 2026
Coverage: Announcements from January 2025 through November 3, 2026.
Pharmaceutical mergers and acquisitions are an important indicator of how drugmakers are positioning their businesses for the next decade.
Companies use acquisitions to replenish pipelines, strengthen therapeutic franchises, acquire approved medicines, access new technologies, enter attractive disease markets, and prepare for future patent expirations.
This tracker follows selected major transactions involving pharmaceutical and biotechnology companies. It records acquisitions by announcement year, including transactions announced in 2025 but completed in 2026.
How to Read This M&A Tracker
The implied value of the target company's outstanding equity based on the announced consideration.
Equity value plus debt and other relevant adjustments, less cash and cash equivalents. EV should not be treated as interchangeable with equity value.
The fixed cash or stock consideration offered to shareholders at closing.
An additional payment that depends on specified future clinical, regulatory, or commercial milestones. The maximum CVR value is not guaranteed consideration.
The acquisition has legally closed, rather than merely having been announced or approved.
A definitive agreement has been announced but the transaction has not yet been completed.
2026 Pharma & Biotech M&A Transactions announced between January 1 and November 3, 2026
Merck KGaA → Silence Therapeutics
Merck KGaA, Darmstadt, Germany, agreed to acquire Silence Therapeutics, a biotechnology company developing precision-engineered medicines using its small interfering RNA (siRNA) platform.
The offer is US$20 per American Depositary Share (ADS), representing an equity value of approximately US$1.3 billion and enterprise value of approximately US$1.1 billion.
Strategic rationale: Strengthen Merck KGaA's targeted medicines capabilities in specialty and rare diseases, including RNA-based therapeutics.
Viatris → Pacira BioSciences
Viatris agreed to acquire Pacira BioSciences for US$36.50 per share in cash, representing an aggregate equity value of approximately US$1.65 billion.
The acquisition brings two commercial products: EXPAREL and ZILRETTA, expanding Viatris' position in non-opioid pain management.
Strategic rationale: Build the innovative medicines business and expand a specialty pain portfolio using Viatris' international infrastructure.
Shionogi → IntraBio
Shionogi agreed to acquire IntraBio, a biotechnology company focused on treatments for neurodegenerative and rare diseases.
The acquisition adds AQNEURSA (levacetylleucine), a treatment approved in the US for neurological manifestations of Niemann-Pick disease type C and for ataxia in patients with ataxia-telangiectasia.
Strategic rationale: Expand Shionogi's global rare disease business and strengthen its commercial presence in specialist neurological conditions.
Vertex Pharmaceuticals → Crinetics Pharmaceuticals
Vertex acquired Crinetics to strengthen its endocrine disease portfolio and diversify beyond its established cystic fibrosis business.
The transaction was valued at approximately US$10 billion in equity value, or approximately US$8.8 billion net of estimated cash acquired.
Strategic rationale: Enter and expand in endocrine diseases with commercial and late-stage development assets.
AbbVie → Apogee Therapeutics
AbbVie agreed to acquire Apogee Therapeutics for US$135.11 per share in cash, representing an equity value of approximately US$10.9 billion.
The transaction adds a portfolio of clinical-stage antibodies targeting inflammatory and immunological conditions.
Strategic rationale: Deepen AbbVie's immunology business and expand its clinical presence in respiratory and dermatological diseases.
GSK → Nuvalent
GSK acquired Nuvalent, a clinical-stage biotechnology company focused on precision oncology and next-generation kinase inhibitors.
The transaction gives GSK access to three lung cancer programmes, including two late-stage targeted therapies.
Strategic rationale: Strengthen oncology capabilities and establish a platform in precision lung cancer treatment.
Johnson & Johnson → Firefly Bio
Johnson & Johnson acquired Firefly Bio and its proprietary Firelink degrader antibody conjugate (DAC) platform.
The platform is designed to deliver selective protein degraders to cancer cells, with an initial focus on pan-KRAS and other difficult-to-treat solid tumours.
Strategic rationale: Expand next-generation antibody engineering and targeted oncology development.
CVC Capital Partners / GBL → Recordati
CVC Capital Partners and Groupe Bruxelles Lambert (GBL), through an acquisition vehicle, launched a public takeover offer for Italian pharmaceutical company Recordati.
The offer price was subsequently raised to €53 per share in October 2026.
Strategic rationale: Take the specialist pharmaceutical company private while providing the financial sponsors with exposure to specialty medicines, rare diseases and self-medication products.
Sun Pharmaceutical → Organon
Sun Pharma agreed to acquire Organon, the global pharmaceutical company spun off from Merck & Co. in 2021.
The proposed transaction values Organon at approximately US$11.75 billion in enterprise value.
Strategic rationale: Expand Sun Pharma's innovative medicines business while acquiring an established global portfolio in women's health, biosimilars and general medicines.
Merck & Co. (MSD) → Terns Pharmaceuticals
Merck & Co., known as MSD outside the US and Canada, acquired Terns Pharmaceuticals to expand its hematology and oncology pipeline.
The transaction represented an equity value of approximately US$6.7 billion, or US$5.7 billion net of acquired cash.
Strategic rationale: Add a differentiated oral targeted therapy for chronic myeloid leukaemia and strengthen the company's hematology pipeline.
Adjacent Life-Sciences M&A Strategically relevant to the pharmaceutical research and manufacturing ecosystem, but not a core drug-company acquisition
Merck KGaA → Bio-Techne
Merck KGaA, Darmstadt, Germany, agreed to acquire Bio-Techne, a US-based life-sciences company supplying research reagents, analytical technologies and bioprocessing solutions.
Strategic rationale: Expand Merck KGaA's exposure to high-growth life-sciences markets, multi-omics, research tools and advanced therapeutic development.
2025 Pharma & Biotech M&A Transactions announced in 2025, including those that closed in 2026
Johnson & Johnson → Halda Therapeutics
Johnson & Johnson acquired Halda Therapeutics and its proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC) platform.
The acquisition adds an investigational platform designed to selectively kill cancer cells and develop targeted oral medicines across solid tumours.
Strategic rationale: Strengthen J&J's oncology pipeline, particularly in prostate cancer, with expansion potential in other solid tumours.
Merck & Co. (MSD) → Cidara Therapeutics
Merck agreed to acquire Cidara Therapeutics, adding its drug-Fc conjugate technology and late-stage antiviral candidate.
Strategic rationale: Expand respiratory and infectious disease capabilities through a potential long-acting influenza prevention medicine.
Novartis → Avidity Biosciences
Novartis acquired Avidity Biosciences, strengthening its RNA therapeutics strategy and neuroscience pipeline.
The transaction valued Avidity at approximately US$12 billion on a fully diluted equity basis, with an enterprise value of approximately US$11 billion.
Strategic rationale: Acquire a differentiated RNA delivery technology platform and late-stage neuromuscular disease programmes.
Pfizer → Metsera
Pfizer acquired Metsera, a biotechnology company developing next-generation obesity and cardiometabolic medicines.
The final deal followed an amended merger agreement in November 2025, with higher consideration and a revised contingent value structure.
Strategic rationale: Strengthen Pfizer's competitive position in obesity and cardiometabolic medicines through a pipeline of injectable and oral candidates.
Merck & Co. (MSD) → Verona Pharma
Merck acquired Verona Pharma to expand its cardio-pulmonary portfolio and add Ohtuvayre (ensifentrine), a treatment for chronic obstructive pulmonary disease (COPD).
Strategic rationale: Strengthen the respiratory medicine franchise with an approved product and potential pipeline expansion.
Sanofi → Blueprint Medicines
Sanofi acquired Blueprint Medicines, adding a commercial rare immunology medicine and a pipeline focused on mast cell disorders and KIT-driven diseases.
Strategic rationale: Strengthen rare disease and immunology leadership while expanding its specialist commercial infrastructure.
Merck KGaA → SpringWorks Therapeutics
Merck KGaA, Darmstadt, Germany, acquired SpringWorks Therapeutics, a commercial-stage biotechnology company focused on rare tumours and severe diseases.
Strategic rationale: Expand rare tumour capabilities in the US and build a stronger global specialist oncology franchise.
Johnson & Johnson → Intra-Cellular Therapies
Johnson & Johnson acquired Intra-Cellular Therapies, adding a commercial neuroscience product and a clinical-stage pipeline.
Strategic rationale: Strengthen neuroscience and mental health capabilities and expand the company's long-term CNS portfolio.
What the Major Pharma M&A Deals Reveal
The transactions in this tracker reveal several recurring strategic priorities across the pharmaceutical industry.
1. Pipeline replenishment and patent-cliff management
Large pharmaceutical companies continue to purchase external innovation to strengthen future revenue pipelines. Acquiring a company with an approved product or a late-stage candidate can potentially shorten the time required to enter a new market compared with developing a medicine entirely in-house.
This is particularly relevant for companies with major products approaching patent expiration, although not every acquisition directly replaces a specific expiring blockbuster.
2. Obesity and cardiometabolic medicines
Pfizer's acquisition of Metsera demonstrates the strategic interest in differentiated obesity medicines beyond conventional GLP-1 receptor agonists.
Next-generation incretin combinations, amylin analogues, oral candidates, longer dosing intervals and potentially better tolerability remain important areas of development.
3. Oncology and precision medicine
Acquisitions involving Nuvalent, Firefly Bio, Halda Therapeutics and SpringWorks illustrate the breadth of oncology investment.
Buyers are acquiring targeted kinase inhibitors, degrader technologies, novel cancer-cell killing platforms and medicines for rare tumours.
4. Immunology and specialty medicines
AbbVie's acquisition of Apogee and Sanofi's acquisition of Blueprint demonstrate continued interest in immunology, inflammatory disease and specialist rare disease markets.
5. RNA and next-generation therapeutic platforms
Novartis' acquisition of Avidity and Merck KGaA's agreement to acquire Silence Therapeutics highlight interest in technologies that enable targeted delivery or gene-specific regulation.
Such technologies can provide strategic value beyond an individual drug candidate, although their long-term clinical and commercial success remains to be demonstrated.
6. Commercial products versus clinical-stage pipelines
Buyers are purchasing different levels of development risk.
- Commercial-stage acquisition: Adds existing products, revenue, market access and established prescriber relationships.
- Late-stage acquisition: Provides access to candidates closer to regulatory decisions and potential commercialisation.
- Early-stage platform acquisition: Provides technology, scientific expertise and pipeline optionality, but with greater development uncertainty.
What to Monitor in Future Pharma M&A Deals
A useful M&A tracker should go beyond recording purchase prices. The following indicators help evaluate whether acquisitions are creating strategic and financial value.
- Patent cliff exposure: Identify the buyer's major products facing loss of exclusivity over the coming years.
- Pipeline replacement: Assess whether acquired medicines can replace declining products or diversify revenue sources.
- Clinical development stage: Record Phase 1, Phase 2, Phase 3, regulatory filing and approved product status at the announcement date.
- Acquisition premium: Compare the offer price against the unaffected share price and relevant trading averages.
- Contingent consideration: Separate upfront purchase price from CVRs, milestones and other conditional payments.
- Debt and capital allocation: Track financing, leverage, expected synergies and potential earnings dilution.
- Regulatory review: Monitor antitrust, foreign investment, shareholder votes and other closing conditions.
- Post-acquisition integration: Evaluate whether acquired products and development programmes progress as originally intended.
Frequently Asked Questions
What is pharmaceutical M&A?
Pharmaceutical mergers and acquisitions refer to transactions in which one pharmaceutical or biotechnology company acquires, merges with or takes control of another company. These transactions may involve commercial medicines, clinical-stage drug candidates, research platforms, manufacturing capabilities or entire businesses.
What is the difference between pharma M&A and licensing?
An acquisition generally involves purchasing control or ownership of a company or business. A licensing agreement grants specific rights to develop, manufacture or commercialise a medicine or technology, usually without purchasing the entire company.
Why do pharmaceutical companies acquire biotechnology companies?
Common reasons include pipeline replenishment, access to innovative technology, entry into new therapeutic areas, acquiring commercial products, strengthening research capabilities and diversifying future revenue.
Why do some deals include contingent value rights?
CVRs allow shareholders to receive additional payments if specified clinical, regulatory or commercial milestones are achieved. They can bridge differences in how the buyer and seller value an investigational product. However, these payments are conditional and may never be made.
Does a large acquisition guarantee commercial success?
No. An acquisition price reflects expectations and negotiation at the time of the transaction. Clinical failure, regulatory delays, competition, reimbursement challenges, manufacturing issues and unsuccessful integration can all reduce the value of an acquired business.
Methodology and Data Limitations
This tracker uses publicly disclosed company announcements, investor relations releases, regulatory filings and selected financial reporting.
- Announcement year determines the year under which a transaction is categorised.
- Completion status is recorded separately from the announcement date.
- Deal values are reported in the currency and valuation basis disclosed by the relevant parties.
- CVRs and contingent payments are identified separately from fixed upfront consideration.
- Foreign-currency estimates are not treated as exact USD transaction values.
- Pending transactions remain subject to their disclosed closing conditions.
.png)
Comments